Andrew Chow
@andrewchowmdphd
Former Thoracic Medical Oncologist @sloan_kettering, current Clinical Director at Merck, opinions are my own.
ID: 1053645474551529472
20-10-2018 13:53:51
140 Tweet
349 Takipçi
265 Takip Edilen
So proud of Susan DeWolf and team for this incredible paper! science.org/doi/10.1126/sc…
Great piece by @Dereklowe — definitely using it in the drug dev class I’m creating at Tufts Biology Department! Impt teaching points about new Rx technologies, “undruggable” targets, and how damned hard it is to make new drugs. science.org/content/blog-p…
Excited to see the latest Charlie Rudin lab paper published in Science Translational Medicine: "Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers". #lungcancer #prostatecancer #SCLC #lineageplasticity science.org/doi/10.1126/sc…
Congrats to my super talented and highly knowledgeable friend Neil Vasan . So we’ll deserved!
Meet Kamal Menghrajani (Kamal Menghrajani, MD, MS): oncologist, entrepreneur, and newly appointed White House Fellow! Passionate about fighting cancer, she's collaborating on President Biden’s Cancer Moonshot Initiative to make a meaningful impact. White House Office of Science & Technology Policy ow.ly/iMX550Q9Pze
Excited to share our article in Cancer Cell on clinical and molecular features of acquired resistance to #immunotherapy in #lungcancer. We identify acquired resistance occurs in over >60% of initial responders and investigate underlying mechanisms. cell.com/cancer-cell/fu…
For everyone interested in #TILcelltherapy and for centers working to implement this therapy, we have published consensus guidelines from the TIL working group. Checklists, patient selection criteria, IL-2 guidelines, etc. We hope you find it helpful! Adam J. Schoenfeld
Check out our new story out in Nature Medicine today: a phase II study of nivolumab in dMMR/hypermutated gynecologic cancers together with my dear friend Claire Friedman MD . link.springer.com/article/10.103… brief summary (thread):
The Lancet Oncology Thanks to The Lancet Oncology for this cool cover image — DLL3 PET lighting up SCLC in storm seas — great collaboration with Jason Lewis Radiochem MSK Salomon Tendler JT Poirier and Mark Dunphy! Novel imaging study at Memorial Sloan Kettering Cancer Center
1 Hot off the press from team Memorial Sloan Kettering Cancer Center in Cancer Discovery! A study solving the puzzle of exceptional new lung cancer type: #Chromothripsis-mediated Small Cell Lung Cancer #SCLC This took nearly a decade and 42 coauthors to unravel. Here are some highlights 👇
Vaccines have made an enormous difference to world health in the last century! via Matthew Herper forbes.com/sites/matthewh…
